Two Scientists Walk Into A Bar

Some types of breast cancer can become “addicted” to estrogen signaling, so treatments that target the estrogen receptor were once thought to be a magic bullet against this disease. But breast cancer is sneaky, and some mutations can allow it to sidestep these types of targeted therapies. In our latest episode, Lori Friedman, Senior Director of Translational Oncology at Genentech, talks about the ways scientists are trying to stay one step ahead of breast cancer.